icon-facebookicon-instagramicon-pinteresticon-soundcloudicon-twittericon-youtube
KappaMab is one of a new class of medicines called monoclonal antibodies under development for use in multiple myeloma. In this study, we are using KappaMab in combination with Lenalidomide and low dose dexamethasone in relapsed refractory multiple myeloma to determine the safety and efficacy of KappaMab. We hypothesize that treatment with KappaMab relatively early in a patient’s disease course will give the patient the greatest benefit.

Recruitment updated as of June 2019.

STUDY DESIGN

Multicentre, open label, sequential cohort study

CORRELATIVE STUDIES

Blood and bone marrow samples are collected for biomarkers to correlate clinical response, patterns of clonal evolution during therapy and assessment of minimal residual disease (MRd) resistance

TRIAL PRINCIPAL INVESTIGATOR

Professor Andrew Spencer and Associate Professor Jake Shortt

TIME FRAME

2016 – 2019

SITE LOCATIONS

  • Alfred Hospital, VIC
  • Monash Medical Centre, VIC
  • Peninsula Oncology Centre, VIC
  • St Vincent’s Hospital, VIC
  • Flinders Medical Centre, SA
  • Peter MacCallum Cancer Centre, VIC

PARTICIPANTS

60 patients with relapsed refractory multiple myeloma (RR MM) who have received 1-3 prior lines of therapy

CURRENT ENROLMENT

Stage 1: 19

Stage 2: 38 

STATUS

Stage 1: Closed

Stage 2: Recruiting